Hsv 1 and 2 Gowey Protocol Versus Placebo

Herpes Clinical Trial

Official title:

Phase II Clinical Trial of Versabase/Sarracenia Purpurea Versus Placebo

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01477879
• Other study ID #: HSV1&2
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: November 15, 2011
• Last updated: November 19, 2011
• Start date: January 2011
• Est. completion date: March 2011

Study information

• Verified date: November 2011
• Source: Naturopaths International
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study will compare efficacy of versabase gel with 20% sarracenia purpurea versus placebo applied every 3-4 hours to herpes lesions.

Description:

Patients screened for hsv one or two. Patients with herpes given a 1/8 oz of gel. Researcher does not know which is active and which is placebo (placebo is actually just versabase gel). Patent applies gel to lesions every 3-4 hours. Returns to clinic on days 3, 5, and 14 for evaluation. Up to 50 patients may be enrolled.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: March 2011
• Est. primary completion date: March 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hsv 1&2

Exclusion Criteria:

• No active lesions

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Herpes

Intervention

Other:
• Versabase gel with sarracenia purpurea 20% liquid extract
Topical application of gel/plant mix to lesions
• placebo (versabase gel only)
versabase gel only

Locations

Country	Name	City	State
United States	Naturopaths international	Flagstaff	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Naturopaths International

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain	Pain scale-- subjective	2 weeks	No
Primary	Size	Measure lesion size over 2 weeks	2 weeks	No
Secondary	Appearance	Photo taken of lesion w patient informed consent	2 weeks	No